Transaction Overview - Recursion and Exscientia are combining to bring better medicines to patients more rapidly and cost efficiently[11] - Exscientia shareholders will receive 0.7729 shares of Recursion Class A common stock for each Exscientia ordinary share[27] - Recursion shareholders will own approximately 74% of the combined company, while Exscientia shareholders will own approximately 26%[27] - The transaction is expected to close by early 2025, subject to shareholder approvals and closing conditions[27] Financial Synergies and Cash Position - The combined company will have approximately $850 million in cash as of the end of Q2 2024[11, 27] - Estimated annual synergies of $100 million or more are expected[11, 27] - The pro forma combined financial plans are expected to extend the cash runway into 2027[27] Pipeline and Partnerships - The combined company anticipates approximately 10 clinical readouts over the next 18 months[11, 12, 14] - Current partnerships have the potential for over $200 million in milestone payments over the next 2 years[11, 18] - The combined company has the potential for over $20 billion in total revenue before royalties from partners[18] - CDK4/6 inhibitors generated $11 billion in sales in 2023[31]

第三是智能能力高阶化。行业往前发展的核心动力是智能能力必须不断进行高阶化演进。今天的人工智 能已经让大家惊叹，但这仅仅是开始。高阶化离不开技术体系化，离不开要素的突破，离不开对形态的 理解。否则，基于中阶过程去探讨人工智能的高阶化，就有可能走上错误的道路。 针对人工智能未来关键技术节点的判断，很多问题至今还没有确定的答案，但对它们的探索和解答至关 重要。回顾科学历史，伟大的技术突破往往是从提出一个关键问题开始。我们期待携手 AI 领域的杰出 研究者，探讨出高价值战略问题，并以之引领，推进人工智能的高质量发展。 围绕智能技术体系化、智能形态多元化、智能能力高阶化这三大趋势，有10个问题值得进一步探讨。 首先，伴随诺贝尔奖纷纷花落人工智能项目，以 AI 赋能创新科学范式被寄予激发人类社会生产力重大 飞跃的特殊意义。而 AI for Science 研究，如何从促进研究的单点突破升维至科研全链条水平的本质飞 升？如何从"工具的革命"，发展至足以引领全新科学范式发展的"革命性工具"？我们仍需在多模态统一 表征方面持续钻研，打造能够推动科学突破的AI系统。 来源：中国新闻网 通用人工智能(AGI)作为人工智能领域的终极 ...

Salesforce (CRM) 2025 Conference June 10, 2025 01:45 PM ET Speaker0 Everybody. Good morning for some. It's Keith Bachman here. We're from BMO. We're sorry we're a touch late. We've run over, I gather, in terms of our virtual conference. But for me, this is my last I'm thrilled to have Salesforce on with us. There's a a few from IR, but we're just gonna go to Susan. And a way to start this is we're gonna ask Susan to give her background before we launch into questions since, as Alex has told me, this is the ...

Recursion Pharmaceuticals (RXRX) Q4 2024 Earnings Call February 28, 2025 08:30 AM ET Company Participants Chris Gibson - Co-Founder & CEOLina Nilsson - SVP Head of PlatformBen Taylor - CFO & President Recursion UK Chris Gibson Welcome everybody to Recursion's learnings call. I'm Chris Gibson, cofounder and CEO, and I'm excited to take you through Recursion's twenty twenty four, twenty twenty five, and the time ahead. So with that, we'll jump into the slides. And I wanna just set the stage, first of all, to ...